glyburide has been researched along with regorafenib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Cui, X; Han, L; Li, Y; Liu, Y; Song, B; Sun, W; Wang, H; Zhang, Y; Zhou, W | 1 |
1 review(s) available for glyburide and regorafenib
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for glyburide and regorafenib
| Article | Year |
|---|---|
siGCD: a web server to explore survival interaction of genes, cells and drugs in human cancers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genes, erbB-1; Genetic Heterogeneity; Glyburide; Humans; Lymphocytes, Tumor-Infiltrating; Neoplasms; Phenylurea Compounds; Precision Medicine; Pyridines; Software; Sorafenib; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2021 |